Details of the Drug-Related molecule(s) Interaction Atlas

General Information of DTT (ID: TT068JH)

• DTT Name: Tissue factor pathway inhibitor (TFPI) DTT Info
• Gene Name: TFPI

Molecule-Related Drug & Molecule List

5 Clinical Trial Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Concizumab	DM1BRWD	Haemophilia A	3B10.0	Phase 3	[1]
PF-06741086	DMW63TQ	Hemophilia	3B10.0	Phase 3	[2]
Tifacogin	DMMO6P0	Sepsis	1G40-1G41	Phase 3	[3]
BAX-499	DM3415L	Factor IX deficiency	3B11	Phase 1	[4]
NN-7415	DMHVIZC	Factor IX deficiency	3B11	Phase 1	[5]

References

• [1] Subcutaneous concizumab prophylaxis in hemophilia A and hemophilia A/B with inhibitors: phase 2 trial results. Blood. 2019 Nov 28;134(22):1973-1982.
• [2] Neutralizing Antibody Assay Development with High Drug and Target Tolerance to Support Clinical Development of an Anti-TFPI Therapeutic Monoclonal Antibody. AAPS J. 2019 Mar 29;21(3):46.
• [3] Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial. JAMA. 2003 Jul 9;290(2):238-47.
• [4] Aptamer BAX 499 mediates inhibition of tissue factor pathway inhibitor via interaction with multiple domains of the protein. J Thromb Haemost. 2013 Jun;11(6):1137-45.
• [5] Safety and pharmacokinetics of anti-TFPI antibody (concizumab) in healthy volunteers and patients with hemophilia: a randomized first human dose trial.J Thromb Haemost.2015 May;13(5):743-54.